HomeBUSINESS
BUSINESS

Tecentriq to Provide New Option for NSCLC: Oncologists
(Apr.16.2018)

Yuichiro Ohe, deputy director of National Cancer Center Hospital
Chugai Pharmaceutical’s anti-PD-L1 antibody Tecentriq (atezolizumab) could become a new option in the treatment of non-small cell lung cancer (NSCLC), oncologists expressed their hope. Tecentriq will be added to the NHI price list on April 18 for an indication of NSCLC. If launched, it will compete with Ono Pharmaceutical’s anti-PD-1 antibody Opdivo (nivolumab) and MSD’s Keytruda (pembrolizumab), both of which are indicated for NSCLC ...
(LOG IN FOR FULL STORY)